Abstracts tagged "ACPA"

Abstract Number: 1108 • 2016 ACR/ARHP Annual Meeting
Protein Citrullinations By PAD Enzymes Promote Dendritic Cell Transdifferentiation into Osteoclast and Generate Targets for RA-Specific Antibodies
Akilan Krishnamurthy¹, Jimmy Ytterberg², Meng Sun¹, Vijay Joshua¹, Heidi Wähämaa¹, Nataliya Tarasova², Khaled Amara¹, Johanna Steen¹, Vivianne Malmström¹, Bence Rethi¹ and Anca I Catrina¹, ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Immature dendritic cells (DCs) can develop into osteoclasts (OCs), however, the mechanisms regulating this differentiation switch are not yet understood. We have shown that…
Abstract Number: 479 • 2015 ACR/ARHP Annual Meeting
How to Recruit Anti-CCP Positive Patients from Primary Care
Jackie L. Nam¹, Laura Hunt¹, Elizabeth M.A. Hensor¹ and Paul Emery^1,2, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom
Background/Purpose: Around 1% of the population test positive for anti-cyclic citrullinated peptide (anti-CCP) antibodies. This biomarker predicts progression to rheumatoid arthritis (RA) but over a…
Abstract Number: 1641 • 2015 ACR/ARHP Annual Meeting
B Cell Depletion with Rituximab in Patients with Rheumatoid Arthritis: Multiplex Bead Array Reveals Kinetics of IgG and IgA Autoantibodies to Citrullinated Antigens
Geraldine Cambridge¹, Lauren J. Lahey², Maria J. Leandro¹, William H. Robinson³ and Jeremy Sokolove⁴, ¹Rheumatology, University College London, London, United Kingdom, ²Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ³VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁴Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA
Background/Purpose: Seropositivity for rheumatoid factors and anti-citrullinated (Cit) protein antibodies (ACPA) are the strongest predictor for clinical response to rituximab (RTX) in rheumatoid arthritis (RA).…
Abstract Number: 499 • 2015 ACR/ARHP Annual Meeting
Efficacy of Tocilizumab Monotherapy in Patients with RA Is Not Influenced By ACPA Positivity
Manfred Herold¹, Peter Fasching², Winfried Graninger³, Raimund Lunzer⁴, Omid Zamani⁵ and Burkhard Leeb⁶, ¹Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, ²Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, ³Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁴Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, ⁵Rheumazentrum Favoriten Vienna, Wien, Austria, ⁶2nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria
Background/Purpose: Rheumatoid arthritis (RA) patients with anti-citrullinated peptide antibodies (ACPA) need a more aggressive therapy (1). Tocilizumab (TCZ) seems to be the biologic with best…
Abstract Number: 2020 • 2015 ACR/ARHP Annual Meeting
Elevated BMI and ACPA Together Increase RA Risk and Independently Accelerate Time to RA
Sara K. Tedeschi¹, Jing Cui², Elizabeth V. Arkema³, Jeffrey A. Sparks¹, Elizabeth W. Karlson¹ and Karen H. Costenbader^1,4, ¹Rheumatology, Brigham & Women's Hospital, Boston, MA, ²Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ³Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology, Immunology & Allergy, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Obesity and anti-citrullinated peptide antibodies (ACPA) are risk factors for RA. We investigated whether body mass index (BMI) and ACPA interact in determining RA…
Abstract Number: 515 • 2015 ACR/ARHP Annual Meeting
Are Changes in Autoantibody Levels Reflecting Change in Prognosis of Rheumatoid Arthritis?
Manuel Unger¹, Farideh Alasti¹, Paul Studenic¹, Josef S. Smolen^2,3 and Daniel Aletaha¹, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ³Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: The presence of rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) is associated with progression of joint damage in patients with rheumatoid arthritis…
Abstract Number: 2565 • 2015 ACR/ARHP Annual Meeting
ACPA Specific IVIG Attenuate Collagen Induced Arthritis in Mice
Shaye Kivity¹, Nina Svetliscky¹, Qusim Odeh¹, Smadar Gertel¹, Howard Amital¹, Omer Gendelman¹, Iris Barshack², Alexander Volkov², Eran Bar-Meir³, Miri Blank¹ and Yehuda Shoenfeld⁴, ¹Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ²Sheba Medical Center, Institute of Pathology, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ³Plastic surgeon Poria Medical Center affiliated to Faculty of medicine in the Galilee Bar-Ilan university, Poria, Israel, ⁴Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel
Background/Purpose: Administration of intravenous-immunoglobulin (IVIg) is a recognized safe and efficient immunomodulatore therapy for many autoimmune diseases. Anti-idiotypic antibody binding to pathogenic autoantibodies was proposed…
Abstract Number: 520 • 2015 ACR/ARHP Annual Meeting
Antibody to Porphyromonas Gingivalis in Pre-Clinical Rheumatoid Arthritis
Brian Coburn¹, Kevin D. Deane², Jess D. Edison³, Geoffrey M. Thiele¹, Michael J. Duryee⁴, Carlos D. Hunter⁴, Jeffrey Payne⁵, Fang Yu⁶, Harlan Sayles⁶, V. Michael Holers², Jill M. Norris⁷, William R Gilliland⁸, Jeremy Sokolove⁹, WH Robinson⁹ and Ted R. Mikuls¹, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ³Walter Reed National Military Medical Center, Bethesda, MD, ⁴Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Epidemiology, University of Colorado Denver, Aurora, CO, ⁸Rheumatology Service, Walter Reed National Military Medical Center, Bethesda, MD, ⁹VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA
Background/Purpose: Periodontitis (PD) has been implicated as an etiologic risk factor in rheumatoid arthritis (RA), an association that is speculated to be related to the…
Abstract Number: 2570 • 2015 ACR/ARHP Annual Meeting
Comparative Analysis of Collagen-Antibody Induced Arthritis and the Arthritis Inhibitory Potential of Specific ACPA in Two Mouse Subspecies Genetically Separated about One Million Years Ago
Christina Grimm¹, Bianka Marklein¹, Zoltan Konthur², Gerd Burmester¹ and Karl Skriner¹, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany
Background/Purpose: Rheumatoid arthritis (RA) is believed to be induced by environmental, genetic and immunological factors. Monoclonal Anti-citrullinated protein/peptide autoantibodies (ACPA) target different citrullinated proteins years…
Abstract Number: 524 • 2015 ACR/ARHP Annual Meeting
Plasma Concentrations of Antibodies to Porphyromonas Gingivalis Are Increased before Onset of Symptom of Rheumatoid Arthritis
Linda Johansson¹, Natalia Sherina², Nastya Kharlamova³, Barbro Larsson², Lena Israelsson⁴, Solbritt Rantapaa-Dahlqvist⁵ and Karin Lundberg³, ¹1Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ²2Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden
Background/Purpose: Chronic periodontitis has been considered as an important determinant in both occurrence and severity of rheumatoid arthritis (RA). It has been hypothesized that citrullination…
Abstract Number: 2584 • 2015 ACR/ARHP Annual Meeting
Prediction of Disease Relapses By Multi-Biomarker Disease Test Activity in Rheumatoid Arthritis Patients Tapering DMARD Treatment
Juergen Rech¹, Axel J. Hueber², Matthias Englbrecht², Stephanie Finzel³, Judith Haschka^4,5, Bernhard Manger², Arnd Kleyer³, Michaela Reiser³, Hans-Peter Tony⁶, Stefan Kleinert⁷, Martin Feuchtenberger⁸, Martin Fleck⁹, Karin Manger¹⁰, Wolfgang Ochs¹¹, Matthias Schmitt-Haendle¹², Joerg Wendler¹³, Florian Schuch¹³, Monika Ronneberger¹³, Hanns-Martin Lorenz¹⁴, Hubert Nüßlein¹⁵, Rieke Alten¹⁶, Jayme Fogagnolo Cobra¹⁷, Joerg C. Henes¹⁸, Klaus Krüger¹⁹ and Georg A. Schett²⁰, ¹medical clinic 3, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Medical Department 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Medical Department II, Medical University of Vienna, St. Vincent Hospital Vienna,, Vienna, Austria, ⁶University Hospital Würzburg, Würzburg, Germany, ⁷Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, ⁸Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁹Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany, ¹⁰Rheumatology Practice Bamberg, Bamberg, Germany, ¹¹Rheumatologist in Private Practice, Bayreuth, Germany, ¹²Rheumatology Practice, Bayreuth, Germany, ¹³Schwerpunktpraxis Rheumatologie, Erlangen, Germany, ¹⁴University Hospital Heidelberg, Heidelberg, Germany, ¹⁵University Erlangen, Nürnberg, Germany, ¹⁶Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ¹⁷Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, ¹⁸Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, ¹⁹Praxiszentrum St. Bonifatius, München, Germany, ²⁰University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: To analyze the role of multi-biomarker disease activity (MBDA) in predicting disease relapses in rheumatoid arthritis (RA) patients in sustained remission, tapering disease modifying…
Abstract Number: 528 • 2015 ACR/ARHP Annual Meeting
RA33 Challenges the Paradigm of Autoantigen Selection in Rheumatoid Arthritis
Maximilian F. Konig¹, Jon Giles², Peter A. Nigrovic³ and Felipe Andrade¹, ¹Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Columbia University Medical Center, NY, NY, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Antibodies against citrullinated proteins (ACPAs) are the autoimmune hallmark of rheumatoid arthritis (RA), and can precede the onset of symptomatic disease by years. By…
Abstract Number: 2590 • 2015 ACR/ARHP Annual Meeting
Anti-Citrullinated Protein Antibody and Radiographic Disease Progression in Rheumatoid Arthritis
Brian Coburn¹, Geoffrey M. Thiele¹, Michael J. Duryee², Fang Yu³, Harlan Sayles⁴, Jeremy Sokolove⁵, WH Robinson⁶, Alan Erickson⁷, Mary Brophy⁸, James R. O'Dell¹ and Ted R. Mikuls¹, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Public Health, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Stanford University, Palo Alto, CA, ⁶VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁷University of Nebraska College of Medicine and VA Nebraska Western Iowa Health Care System, Omaha, NE, ⁸VA Boston Heathcare System, Boston, MA
Background/Purpose: Anti-citrullinated protein antibody (ACPA) positivity is associated with more rapid radiographic progression in rheumatoid arthritis (RA). A majority of prior studies, however, have assessed…
Abstract Number: 586 • 2015 ACR/ARHP Annual Meeting
Titer of Anti-Citrullinated Peptide Antibody Affects the Efficacy of First Biological Treatment in Rheumatoid Arthritis
Yoshikazu Ogawa¹, Nobunori Takahashi², Koji Funahashi², Shuji Asai³, Toki Takemoto³, Tatsuo Watanabe³, Nobuyuki Asai², Naoki Ishiguro⁴ and Toshihisa Kojima², ¹orthopedic surgery, Nagoya University Hospital, Nagoya, Japan, ²Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ³Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Anti-citrullinated protein antibody (ACPA) has been an important marker in diagnosing rheumatoid arthritis (RA). Its predictive value remains unclear; therefore, here we investigated whether…
Abstract Number: 2595 • 2015 ACR/ARHP Annual Meeting
Autoantibodies to Citrullinated Fibrinogen, Anti-CCP2 and Anti-MCV Antibodies in Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression at 1-Year
Yannick Degboé¹, Arnaud Constantin², Delphine Nigon³, Gabriel Tobon⁴, Martin Cornillet⁵, Thierry Schaeverbeke⁶, Gilles Chiocchia⁷, Pascale Nicaise-Roland⁸, Leonor Nogueira⁹, Guy Serre^5,10,11, Alain G. Cantagrel¹² and Adeline Ruyssen Witrand^13,14, ¹Rheumatology, Rheumatology Center, Purpan University Hospital, Toulouse, France, ²Inserm U558, Rheumatology Center, Purpan University Hospital, Toulouse, France, ³CHU Purpan, Toulouse, France, ⁴Rheumatology Department, la Cavale Blanche Hospital, Brest, France, ⁵Service de Biologie Cellulaire, C.H.U. Purpan, Toulouse, France, ⁶CHU Bordeaux, Bordeaux, France, ⁷Immunology-Rheumatology, INSERM U1173, paris, France, ⁸Immunology Department, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France, ⁹Immunology, UMR CNRS 5165, INSERM 1056, Toulouse, France, ¹⁰Cell Biology, Purpan University Hospital, Toulouse, France, ¹¹Unité Différenciation Épidermique et Autoimmunité Rhumatoïde, Unité Mixte de Recherche, INSERM,Toulouse, France, Toulouse, France, ¹²Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ¹³Rheumatolgy, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ¹⁴UMR 1027, Inserm, Toulouse, France
Background/Purpose: We compared the ability of anti-CCP2, anti-mutated citrullinated vimentin (anti-MCV) and anti-citrullinated fibrinogen (AhFibA) antibodies to predict 1-year rapid radiographic progression (RRP; total Sharp…

« Previous Page
1
…
5
6
7
8
9
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].